Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization
- PMID: 11208826
- DOI: 10.1200/JCO.2001.19.2.354
Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization
Abstract
Purpose: The objective of our study was to compare the methods used in the literature to analyze HER-2/neu status on archival breast cancer tissue. Therefore, a series of antibodies was evaluated to assess their immunohistochemical (IHC) sensitivity in correlation to gene amplification determined by fluorescence in situ hybridization (FISH).
Materials and methods: HER-2/neu overexpression was studied on paraffin sections of 85 invasive breast cancers using a panel of five monoclonal (9G6, 3B5, CB11, TAB250, GSF-HER2) and two polyclonal antibodies (A8010, A0485) in addition to the HercepTest (DAKO, Glostrup, Denmark). HER-2/neu gene amplification was determined by FISH using a dual-color probe (PathVysion; Vysis, Stuttgart-Fasanenhof, Germany).
Results: HER-2/neu overexpression was demonstrated in 26% (9G6, TAB250, GSF-HER2), 27% (3B5, CB11), 33% (A8010) and 42% (A0485, HercepTest) of the tumors. FISH on paraffin sections identified gene amplification in 28% of the tumors. Strongly positive IHC results (3+) were always associated with gene amplification. Among the 16 tumors presented with weakly positive IHC results (2+) using the HercepTest, 12 (75%) lacked gene amplification.
Conclusion: The comparison of IHC and FISH demonstrated an excellent correlation of high-level HER-2/neu overexpression (3+) with gene amplification; ie, FISH does not provide further information in these tumors. However, weakly positive IHC results (2+) obtained with the HercepTest share only a minor association with gene amplification.
Similar articles
-
HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization.Mod Pathol. 2001 Nov;14(11):1079-86. doi: 10.1038/modpathol.3880440. Mod Pathol. 2001. PMID: 11706067
-
HER-2 status in breast cancer: correlation of gene amplification by FISH with immunohistochemistry expression using advanced cellular imaging system.Appl Immunohistochem Mol Morphol. 2006 Jun;14(2):132-7. doi: 10.1097/01.pai.0000150516.75567.13. Appl Immunohistochem Mol Morphol. 2006. PMID: 16785779
-
Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry.J Clin Oncol. 2000 Nov 1;18(21):3651-64. doi: 10.1200/JCO.2000.18.21.3651. J Clin Oncol. 2000. PMID: 11054438
-
[HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].Ann Pathol. 2011 Dec;31(6):472-9. doi: 10.1016/j.annpat.2011.10.013. Epub 2011 Nov 26. Ann Pathol. 2011. PMID: 22172120 Review. French.
-
Prognostic and predictive value of c-erbB-2 (HER-2/neu) gene amplification in human breast cancer.Breast Cancer. 2001;8(1):38-44. doi: 10.1007/BF02967476. Breast Cancer. 2001. PMID: 11180764 Review.
Cited by
-
HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?Int J Mol Sci. 2023 May 4;24(9):8206. doi: 10.3390/ijms24098206. Int J Mol Sci. 2023. PMID: 37175916 Free PMC article. Review.
-
The Clinical Utility of Droplet Digital PCR for Profiling Circulating Tumor DNA in Breast Cancer Patients.Diagnostics (Basel). 2022 Dec 5;12(12):3042. doi: 10.3390/diagnostics12123042. Diagnostics (Basel). 2022. PMID: 36553049 Free PMC article. Review.
-
Co-expression effect of LLGL2 and SLC7A5 to predict prognosis in ERα-positive breast cancer.Sci Rep. 2022 Oct 3;12(1):16515. doi: 10.1038/s41598-022-20225-4. Sci Rep. 2022. PMID: 36192404 Free PMC article.
-
Can HER2 1+ Breast Cancer Be Considered as HER2-Low Tumor? A Comparison of Clinicopathological Features, Quantitative HER2 mRNA Levels, and Prognosis among HER2-Negative Breast Cancer.Cancers (Basel). 2022 Aug 31;14(17):4250. doi: 10.3390/cancers14174250. Cancers (Basel). 2022. PMID: 36077795 Free PMC article.
-
Role of hormone receptors and HER2 as prospective molecular markers for breast cancer: An update.Genes Dis. 2020 Dec 17;9(3):648-658. doi: 10.1016/j.gendis.2020.12.005. eCollection 2022 May. Genes Dis. 2020. PMID: 35782984 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous